Bay Colony Advisory Group Inc d b a Bay Colony Advisors Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 28.3% in the 4th quarter, HoldingsChannel reports. The firm owned 4,933 shares of the company’s stock after selling 1,950 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in CRISPR Therapeutics were worth $309,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Jump Financial LLC raised its holdings in CRISPR Therapeutics by 194.7% during the third quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock worth $1,512,000 after purchasing an additional 22,006 shares in the last quarter. Baker Chad R purchased a new position in CRISPR Therapeutics in the third quarter valued at about $2,365,000. Capital Advisors Inc. OK increased its holdings in CRISPR Therapeutics by 7.4% in the third quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company’s stock valued at $10,527,000 after buying an additional 15,951 shares in the last quarter. Invesco Ltd. increased its holdings in CRISPR Therapeutics by 1.5% in the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after buying an additional 2,061 shares in the last quarter. Finally, ARK Investment Management LLC increased its holdings in CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after buying an additional 1,372,986 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares of the company’s stock, valued at $470,740.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares of the company’s stock, valued at $470,740.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold a total of 114,410 shares of company stock valued at $7,984,677 over the last quarter. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $58.72 on Tuesday. CRISPR Therapeutics AG has a 1 year low of $37.55 and a 1 year high of $91.10. The firm’s 50 day moving average price is $73.89 and its 200 day moving average price is $63.30.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. The business’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same period in the prior year, the business earned ($1.41) EPS. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of research analyst reports. Barclays increased their target price on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Wells Fargo & Company increased their target price on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Mizuho increased their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Finally, Royal Bank of Canada increased their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $74.93.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.